Significant innovation in disease treatment, including the increased focus on complex biologic therapies1, has resulted in important industry trends that have had an impact on many aspects of aseptic processing.
While the requirements for serialization in the pharmaceutical supply chain are generally regarded as inevitable counterfeiting is simply too large of a problem to not be addressed there is some uncertainty around the specifics,particularly globally.
Digital technology has been driving change throughout the life science industry for years, however the sector is currently standing on the precipice of revolutionary development – some organizations have already taken the jump towards a more digital future.
The Falsified Medicines Directive 2011/62/EU, which is due for adoption in February 2019, will require pharmaceuticalcompanies to apply serialisation codes to every applicable pack (OTC and some minor exemptions).
When it comes to the manufacturing of drugs, particularly highly sensitive biologics, a high-level of expertise is required. Typically, small and medium-sized pharma and biotech companies lack the knowledge and know-how necessary to cover all the processes independently prior to completion of the entire final product.
Interview & Whitepapers
News & Press Releases
Boehringer Ingelheim, the world’s second largest animal health company, has been boosting its investment in China by expanding the Asian Veterinary Research & Development (R&D) Center to enhance its research and innovation capacity.
Mitsubishi Tanabe Pharma Corporation MTPC announced that Canagliflozin received the Technology Award Grand Prize at the 50th JCIA Awards.
CPhI & P-MEC China (#CPhIChina) – organized by UBM and UBM SINEXPO – takes place at the Shanghai New International Expo Center (SNIEC) on 20-22nd June 2018.
Aptar Pharma, a leading drug delivery systems provider, is pleased to be exhibiting once again at CPhI China 2018, taking place from June 20-22 at the Shanghai New International Exhibition Center, Shanghai, China.
Lonza announced the addition of hepatic stellate cells, Kupffer cells and liver-derived endothelial cells to its extensive hepatocytes portfolio.
- 04 September 2018 - 07 September 2018
- Hynes Convention Center, Boston, MA
- 19 June 2018 - 21 June 2018
- Amba Hotel Marble Arch
- London, UK
- 10 April 2018 - 11 April 2018
- The Hotel Brussels, Brussels
- 11 April 2018 - 13 April 2018
- National Exhibition and Convention Center,
- 02 May 2018 - 06 May 2018
- Barcelona, Spain
Biogen and Neurimmune announced that Biogen has exercised its option to further reduce the previously negotiated royalty rates payable on potential future sales of aducanumab, Biogen’s Phase 3 investigational treatment for early Alzheimer’s disease.
IDIFARMA has announced new GMP spray drying capabilities which will make it one of the very few contract development and manufacturing organisations (CDMO) to offer spray drying technology for highly potent drugs up to Category 4 OEL/OEB.
Roche Holding AG (ROG.EB) said that a phase 3 IMpower150 study showed an improvement in the treatment of advanced lung cancer with the use of Tecentriq.
AstraZeneca and MedImmune, its global biologics research and development arm, announced top-line results from the GALATHEA Phase III trial for Fasenra (benralizumab) in patients with moderate to very severe COPD .
Planegg (pta/08.05.2018/07:30) Medigene AG (MDG1, Frankfurt, Prime Standard), announced that researchers from Max-Delbrück-Center for Molecular Medicine (MDC) and Charité, both in Berlin, Germany, will present an update on the clinical trial preparations concerning a MAGE-A1-specific T cell receptor clinical investigator-initiated trial (IIT) at the 16th Cancer Immunotherapy Conference (CIMT) in Mainz, Germany, from 15 - 17 May.
Nordic Nanovector ASA announces that a poster reporting the anti-tumour effect of Humalutin® (177Lu-conjugated humanized anti-CD37 antibody, 177Lu-NNV003) in preclinical models of non-Hodgkin's lymphoma (NHL) was presented yesterday at the American Association of Cancer Research (AACR) Annual Meeting 2018 in Chicago, USA.
Medical technology company IME Technologies, developer, producer and scientific partner in the field of biomedical electro spinning processes and equipment, has moved its operations from Geldrop to a significantly larger facility in Waalre with effect from 26 March.
Switzerland-based contract development and manufacturing organisation (CDMO) Micro-Sphere has successfully completed the Swissmedic inspection of its expanded facility, resulting in the renewal of its GMP approved status and increased manufacturing capacity.
Global contract packaging organisation, Tjoapack, has signed a five-year agreement with Photocure for the packaging of its proprietary bladder cancer detection products.
Product life cycle management (PLM) is now a critical area of focus for any pharmaceutical marketer. It’s no longer enough to simply get a drug to market – maintaining success, meeting different market requirements and profitability throughout its life is just as important.
Clariant, a world leader in specialty chemicals, turns the spotlight on its increasing on-the-ground support and innovation focus for North America’s four key plastics application segments at NPE 2018 Booth S18155.